Evidence map›Paper›PMID 38863902›Full record

ArticleFrontiers in cardiovascular medicine2024

Loss of protein phosphatase 2A regulatory subunit

Florentina Pluteanu, Dennis Glaser, Fabian Massing, Jan S Schulte, Uwe Kirchhefer

Abstract read
In one paragraph

Article in Frontiers in cardiovascular medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Florentina PluteanuDepartment of Anatomy, Animal Physiology and Biophysics, University of Bucharest, Bucharest, Romania.
Dennis GlaserInstitut für Pharmakologie und Toxikologie, Universitätsklinikum Münster, Universität Münster, Münster, Germany.
Fabian MassingInstitut für Pharmakologie und Toxikologie, Universitätsklinikum Münster, Universität Münster, Münster, Germany.
Jan S SchulteInstitut für Pharmakologie und Toxikologie, Universitätsklinikum Münster, Universität Münster, Münster, Germany.
Uwe KirchheferInstitut für Pharmakologie und Toxikologie, Universitätsklinikum Münster, Universität Münster, Münster, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Protein phosphatase 2A (PP2A) is a serine/threonine-selective holoenzyme that controls Ca Methods: The aim of this study was therefore to investigate the role of PP2A-B56α in the propensity for arrhythmic activity in the heart. The experimental analysis of this question has been addressed by using a mouse model with deletion of the PP2A-B56α gene, Results: ECG measurements showed a prolongation of QT time in KO vs. WT. KO mice exhibited a higher rate of premature ventricular contractions in the ECG. MAP measurements in Langendorff-perfused KO hearts showed increased episodes of ventricular tachyarrhythmia induced by PES. However, the KO hearts showed values for MAP duration that were similar to those in WT hearts. In contrast, KO showed more myocardial cells with spontaneous arrhythmogenic Ca Conclusion: These findings support the assumption that a decrease or even the loss of PP2A-B56α leads to an increased propensity of triggered arrhythmias. This could be based on the increased spontaneous Ca

Indexed as

Ca2+ transientselectrocardiogramK+ channel currentsmonophasic action potentialPPP2R5A/B56αprotein phosphatase 2Aventricular tachyarrhythmia

Identifiers

PMID38863902
PMCPMC11165201

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.